Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03098979 · ClinicalTrials.gov registry record · Phase 2
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 305
- Enrollment target
NCT03098979 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 305 participants.
The verdict
NCT03098979, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 305 participants
- Enrollment target
Study Summary
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.
Interventions
- DRUG Neladenoson bialanate (BAY1067197)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2017-05-10 |
| Est. Completion | 2018-06-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03098979
The ClinicalTrials.gov registry entry for NCT03098979 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neladenoson bialanate (BAY1067197) is the first listed.
NCT03098979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03098979 about?
NCT03098979 is a clinical study titled "A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction". The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.
What is the current status of trial NCT03098979?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 305 participants. The study started on 2017-05-10. Estimated completion is 2018-06-20.
What interventions are being tested in trial NCT03098979?
The interventions under investigation include: Neladenoson bialanate (BAY1067197) (DRUG).
Who is sponsoring clinical trial NCT03098979?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.